Risperidone in chronic schizophrenia: A detailed audit, open switch study and two-year follow-up of patients on depot medication

European Psychiatry

Volumn 17, Issue 8, 2002, Pages 459-465

  Conlon, L ^a   Fahy, T J ^a   O'Toole, R ^a   Gilligan, J ^a   Prescott, P ^b  

^a UNIVERSITY HOSPITAL GALWAY   (Ireland)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Audit; Depot; Follow up; Risperidone; Schizophrenia; Switch study

Indexed keywords

ANTIPARKINSON AGENT; FLUPHENAZINE; NEUROLEPTIC AGENT; RISPERIDONE; THIORIDAZINE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DROWSINESS; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; INSOMNIA; LEG PAIN; MALE; MEDICAL AUDIT; MUSCLE WEAKNESS; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SURVIVAL; TREATMENT OUTCOME; VERTIGO;

EID: 0036928440     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-9338(02)00709-5     Document Type: Article

References (20)

1. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res 1990;3:247-51.
2. American Psychiatric Association. Global Assessment of Functioning, Axis IV. Diagnostic and Statistical Manual of Mental Disorders. Washington (DC): APA; 1994 4th ed.
3. Andreasan NC. The Scale for the Assessment of Negative Symptoms (SANS). Iowa City (IO): The University of Iowa; 1983.
4. Barnes T. A rating scale for drug induced akathisia. Br J Psychiatry 1989;154:672-6.
5. Chouinard G, Ross-Chouinard A, Annable L, Jones BD. The extrapyramidal symptom rating scale. Can J Neurol Sci 1980;7(3):233.
6. David AS. Insight and psychosis. Br J Psychiatry 1990;156:798-808.
7. Desai NM, Huq Z, Martin SD, McDonald G. Switching from depot antipsychotic to risperidone: Results of a study of chronic schizophrenia. Adv Ther 1999;16(2):78-88.
8. Heinrichs DW, Hanlon ET, Carpenter Jr WT. The Quality of Life Scale: An instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984;10:388-98.
9. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity. Psychol Med 1983;13:177-83.
10. Jeste DV, Klausner M, Brecher M. A clinical evaluation of risperidone in the treatment of schizophrenia: A 10-week, open-label, multicentre trial. Psychopharmacology 1997;131:239-47.
11. Kay SR, Fiszbein A, Opler LA. The positive and negative syndromescale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
12. Kemp R, Hayward P, Applewhaite G, et al. Compliance therapy in psychotic patients: Randomised controlled trial. Br Med J 1996;312:345-9.
13. Kirov GK, Murray RM, Seth RV, Feeney S. The Risperidone Switching Study Group. Observations on switching patients with schizophrenia to risperidone treatment. Acta Psychiatr Scand 1997;95:439-43.
14. Larsen EB, Gerlach J. Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics. Acta Psychiatr Scand 1996;93:381-8.
15. McGrath J, Emmerson WB. Treatment of schizophrenia. Br Med J 1999;319:1045-8.
16. Periera S, Pinto R. A survey of the attitudes of chronic psychiatric patients living in the community towards their medication. Acta Psychiatr Scand 1997;95:464-8.
17. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970(Suppl 212):11-9.
18. US Department of Health, Education and Welfare. Abnormal involuntary movement scale (AIMS). In: Guy W, editor. ECDEU Assessment Manual. 1976. p. 534-7.
19. Walburn J, Gray R, Gournay K, Quaraishi S, David AS. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001;179:300-7.
20. Wilkinson G, Hesdon B, Wild D, Cookson R, Farina C, Sharma V, et al. Self-report quality of life measure for people with schizophrenia: The SQLS. Br J Psychiatry 2000;177:42-6.